Alzheimer's disease (AD) is the most common neurodegenerative disorder. Along with an increasing number of elderly worldwide it poses a great challenge for the society and healthcare. Although sporadic AD is the common form of AD, 2-3% of the AD cases are expected to be due to mutations in the beta region of the amyloid precursor protein which is referred to as autosomal dominant AD (ADAD).
INTRODUCTION
Alzheimer's disease (AD) is the most common form of dementia as well as a neurodegenerative disorder. 2 The amyloid (Aβ1-42) deposits remain as the pathological hallmark of AD and the Aβ cascade hypothesis is widely accepted by the scientific community. 3 Molecular imaging enables the identification of Aβ fibrils in vivo and is clinically used in the diagnosis of AD. Thus the three PET tracers 18 F-florbetapir, 18 Fflorbetaben and 18 
F-flutemetamol (FPIB) have been approved by the US Food and Drug
Administration and the European Medical Association (EMA) for use in clinical assessment of memory impairment to exclude AD. 4 Clinically, AD can be divided into early-onset (ie younger than 65 years) and lateonset (ie, older than 65 years), whereas pathologically it is characterised by the presence of amyloid β peptide plaques and intra-neuronal tangles of hyperphosphorylated forms of the tau protein (microtubule-associated protein tau, MAPT). 5 Early-onset AD accounts for about 5-10% of all AD cases among which 13% comprise the familial AD. These familial mutations can also be called autosomal dominant Alzheimer's disease (ADAD) as they are occurring via autosomal dominant inheritance. 6 In addition sporadic mutations in Alzheimer's disease are also observed.
Some of the widely known ADAD mutations are the Arctic, Italian, Dutch, Iowa and Flemish variants. [7] [8] [9] [10] [11] It has been observed from previous experimental studies that the rate of fibril formation generally increases in those familial mutations, the Flemish variant being an exception. [12] [13] [14] [15] [16] Earlier experimental studies have also shown that the commonly occurring familial mutations only marginally affect the predominant β-sheet conformation of the Aβ42 peptide, 17 so that the basic β-sheet dominated structure of Aβ42 is retained in the mutated systems while the kinetics, i.e the rate of fibril formation, varies among the mutant systems with respect to the wild Aβ42. Apart from the above mentioned mutations many other types of mutations referring to the amyloid precursor protein (APP) have been observed, however, they are present in the residues preceding the Aβ1-42 structural region and are mainly involved in the rate of formation of Aβ42 peptides which in turn affects the aggregation and consecutive effects. C-AZD2184 . 18 In vivo PET studies with 11 C-PIB have been unable to demonstrate the fibrillar plaques in brain carriers of the Arctic form of early-onset AD. 19 However, in vitro studies on the binding of PIB (Pittsburgh compound -B) to wild type Aβ42 and the Arctic protofibril has also recently been published which shows that the 3 H-PIB compound can bind to the protofibrils of Arctic Aβ42. 20 The above observations illustrate the importance of understanding the interaction of commonly used PET tracers for Alzheimer's disease with the different mutant structures of Aβ42.
Computational studies of the protein-ligand complexes have an innate advantage of obtaining molecular level information on the underlying interaction process which can be useful in interpreting the experimental observations. In order to have an atomistic picture of the interaction of PET tracers with different mutations in Aβ42 we have carried out a modelling study using several ADAD mutations including the Arctic, Italian, Dutch, Iowa, Flemish mutations along with the native Aβ42 using the most widely used and experimentally studied PET tracers, namely Florbetapir, Florbetaben, FPIB, AZD4694 and AZD2184. The reason for choosing these specific mutations is because in these cases the mutated residues are present in the Aβ42 structural regions which can directly influence the interaction with the PET tracers. It is notable that the Flemish mutation is considerably different from the other mutants in several ways; their neurotoxicity is slightly reduced with respect to the native Aβ42; their fibrillization rate is slower compared to that of the native Aβ42; they are characterised by vascular deposition of the amyloid. We included this system in our study because this is the only mutation present in the APP structural region of Aβ42 with considerably contrasting features with respect to native Aβ42 in comparison to the other mutants. 21 The variation in the mode of interaction between the various mutated amyloid peptides and different PET tracers depends on few important factors -one being the conformational change induced by the mutated residue in the amyloid structure, a second factor is the direct involvement of the mutated residue on the interaction with the PET tracers and a third being that the structure of the PET tracer itself is favourable to some mutations and not favourable to other mutants. Thus the molecular level understanding on the stability of these complexes may shed light on some of the earlier results observed from in-vivo and clinical studies. We recall that the chemical accuracy of the currently available force-field methods is not sufficient to distinguish compounds having binding affinity in the subnanomolar range. Free energy calculations using the free energy perturbation (FEP) approach has been reported with the standard error 0.6 kcal/mol while docking methods are associated with the range around 2.5 kcal/mol and these results are mostly system specific. 22 The molecular mechanics energies combined with the generalized Born and surface area continuum solvation (MM/GBSA) method and with molecular dynamics simulations (MD) is known to perform better than docking but is known to sometimes underperform when compared to the FEP approach. A recent study by Wang and co-workers illustrate that MM/GBSA is capable of capturing the experimental binding profile of various protein-ligand complexes similar in line with FEP methods despite the incorrect prediction of the binding mode for one of the ligands. 23 The standard errors are known to be lower for biomolecular targets having rigid protein backbone and well defined binding sites. However, this has not been assessed in detail for targets with considerable flexibility like in the case of the amyloid beta protofibrils. Moreover, the absolute value of the binding free energy has little significance in force-field methods and so the assessment of the results is based on the relative binding free energies when compared to a reference system (here native type amyloid beta fibril). In all, the MM/GBSA results here presented may be helpful in identifying the suitability of presently used PET tracers in detecting the amyloid condition in different mutated variants of AD.
RESULTS AND DISCUSSION

Docking
The three possible core docking sites on the Aβ42 fibril are illustrated in Figure 1 (we refer to the computational details section for further information about different core binding sites).
The results of the docking carried out using the selected PET tracers onto the native and mutant variants of the Aβ42 peptide are presented in Table 1 . All five PET tracers seem to bind to all possible core binding sites except for three specific cases (AZD2184 in Italian mutation, AZD4694 and FPIB in Iowa mutation). The docking energy values indicate that the S1 site was favourable for the native and mutant peptides in most of the cases irrespective of the PET tracers. In three specific cases, i.e florbetaben in Dutch mutation, florbetaben and AZD2184 in Iowa mutation, the S2 site is found to be ambiguously more favourable than the S1 site .
We know from our previous studies that MD simulation results may vary from that of the docking results due to various factors such as solvation and protein flexibility. [24] [25] [26] We therefore cross checked our result of these ambiguous systems using MD. The results for 17 nanosecond (ns) run are given in Table 2 . It is found from the MD MM/GBSA results that the S1 site is more favourable in terms of energy and so we focussed on the Aβ42-ligand complexes at the S1 site for the rest of the studies.
Structural analysis
The different type of Aβ42 mutants used in this study and their details are presented in Table 3 . As we are simulating the native Aβ42 and also their mutated systems it is essential to carry out structural analysis to understand the effect of mutation on the structural aspects of Aβ42 which can be compared with the previous experimental observations. 17 Before doing the analysis, it is essential to assess whether the simulation is well equilibrated by means of a The secondary structure content of the Aβ42 in different systems for the last 10 ns of the simulation was calculated and tabulated in Table 4 . The results indicate that the beta content of Aβ42 varies with different mutants and also with the different PET tracers.
However, it is relevant to mention that the total beta content varies from a minimum of 38% to a maximum of 59 %. On the whole it is observed that the predominant beta fibril nature of Aβ42 is not affected by the mutation. An earlier in-vitro study regarding the aggregation of the Aβ42 and its different mutant peptides by Annelies et al also showed that the predominant beta nature of the peptide is retained. 16 Thus it is understandable that the overall beta fibril nature of the peptide is retained even after these mutations. As the fibril nature of Aβ42 is an essential requirement for the interaction of PET tracers, the predominant fibril nature of the mutations indicate that their interaction with PET tracers may be retained.
MM/GBSA results
The experimental binding affinity of the PET tracers identified with the Aβ fibril were collected from literature and presented in the Table 5 . These values are used as a guideline to check the binding affinities calculated using the MM/GBSA approach for the native system. The results indicate that all the PET tracers have a favourable binding energy with the native and mutant Aβ42 although there is some significant reduction in terms of magnitude in some specific cases. The interaction of thioflavin-t (THT)-like molecules, i.e. AZD4694 and AZD2168, with the mutant systems is weakened in all cases in comparison to the native one, except Iowa-AZD4694 where there is a slight increase of 3.4 kcal/mol. It is also noticeable that the gain in energy is due to the solvation component of the system whereas the direct interactions, van der Waals and electrostatic, are not much changed. It is also notable that the AZD2184 binding to the Flemish mutant is the weakest among all the systems with a mere 8.5 kcal/mol binding energy owing to drastic reduction in terms of electrostatics and van der Waals energy. As the Flemish mutant is considerably different from other mutants in terms of their neurotoxicity and fibrillation, it is notable that we here find that the Flemish mutants in general possess weaker binding affinities to the tracers among all the studied systems. We also find that AZD4694 and AZD2184 bind to the mutant peptides satisfactorily even though there is a slight decrease in the magnitude of interaction energy except for Flemish-AZD2184. The latter has been reported to bind with high affinity in vitro both in sporadic and ADAD autopsy brain tissue. 18 The in vitro binding data can be interpreted in such a way that although there is a decrease in the magnitude of interaction of AZD2184 to the mutant peptide (except Flemish mutant) on comparing to the native system. In the case of ADAD, an increased production and deposition of amyloid plaques (except Flemish mutant) which means a larger amount of Aβ42 is available for the PET binding that might explain why 
Residuewise contributions to the binding
The residuewise MM/GBSA energy contributions of each system are presented in Figure 5 . This analysis can give insight about the role of each residue for the interaction between Aβ42 and the PET tracer. The illustrated results indicate that the major factors ambiguously driving the favourable interaction between the complexes are the hydrophobic residues such as phenyl alanine and valine. In our previous studies we stressed the importance of the NMR conformation 8 of 2BEG where the phenyl alanine core have the most favourable interaction site. [24] [25] [26] The results from the residue-wise break up of the MM/GBSA contribution substantiate our earlier findings: In the case of florbetaben, in addition to the phenylalanine and valine, the leucine residues make a significant contribution towards a favourable interaction. We observe from the plot that for Iowa-AZD4694 there is a stronger interaction of the phenyl alanine and valine residues compared to the native system which may explain the exceptional nature of this mutation in that it has more favourable interaction energy than the native system. There is another exceptional case: ArcticFlorbetaben shows a significant decrease in the interaction energy with respect to the native system. A corresponding decrease in the contribution of key residues, such as phenyl alanine and valine, is observed for this complex when comparing with the native system.
As we are here dealing with the mutations involving three residues, namely alanine (A) 21, glutamic acid (E) 22 and aspartic acid (D) 23, of the Aβ42, it is important to monitor the contributions of these residues to the interaction energy. For this purpose we separately plotted the contributions of AED in the native Aβ42 i.e residues 21-23 (for all 5 chains) in all the systems separately and presented the results in Figure 6 . This gives a closer view about the effect of these mutated residues in the interaction process. In the earlier discussion we found that Dutch-FPIB has a favourable interaction which can be understood from the results for the mutated residue interaction where the three consecutive AED triads favourably interact with FPIB in comparison to the native system. Similarly, we also observed a reduction in the Arctic and Iowa mutations with florbetaben which is understood by analysing the mutated residue contributions. The plot in Figure 6 indicates that the native system has a more favourable energy contribution in terms of the 21-23 residues comparing with the Arctic and Iowa systems. In the case of Arctic-Florbetaben system, hydrophobic residues, such as phenyl alanine, valine, and the residues around point mutation site (residue 22) are contributing to the increase in total binding free energy when compared to the native system.
In the case of Flemish-AZD2184, the residues around the mutation site contribute more favourably to the binding when compared to native fibril. This illustrates the predominance of the hydrophobic core residues in dictating the Aβ42-PET interaction process. Thus it can be understandable from these results that a multitude of factors are responsible in determining the interaction process between Aβ42 and PET tracers, some of the important ones are the conformation of the Aβ42 peptide and the chemical nature of the ligand. In case of mutations further factors such as the conformational change induced by the mutation (which indirectly leads to the change in the hydrophobic core residues of the Aβ42) as well as the direct interaction of the mutated residues with the PET tracer also play important roles in determining the interaction pattern of atracer with Aβ42.
Arctic mutation
In-vitro studies of the Arctic mutation show that they are forming fibrils whereas earlier clinical studies and pathological studies have shown Aβ plaques devoid of congophilic Aβ cores, indicating a lack of β-pleated sheet formation. 17, 19 A recent detailed postmortem study of plaque pathology associated with the APParc mutation reported the presence of C-and Nterminally truncated forms of Aβ that are specific for the "Arctic" plaques. 27 Clinical studies show that there is a low level of C-PIB retention in the case of Arctic mutation whereas recent in-vitro studies show that H-PIB can recognise the Arctic Aβ42 protofibril prepared invitro and oligomers. 19 Thus it seems to be a difference between the Arctic Aβ42 in the in-vitro condition and in the clinical form. 
Conclusions
The aim of the present study was to find some underlying factors for the changes in the interaction pattern of PET tracers related to mutation induced structural changes in amyloid fibrils which could be useful in selecting appropriate tracers for the diagnosis purpose and for 
COMPUTATIONAL DETAILS Protein
The structure of Aβ42 from the protein data bank (PDB) with PDB ID 2BEG is taken as the proteins structure which is a pentamer. 28 It is well established that the amyloid exist predominately in two forms Aβ40 and Aβ42, here we selected Aβ42 because this form is found to play an important role in the amyloid toxicity and they are found in increased concentrations in brains of patients with familial Alzheimer's disease. 29 It is known from the previous studies that the mutations such as Arctic, Italian, Dutch, Iowa and Flemish mutations differ from the wild type amyloid peptides in terms of aggregation kinetics but predominately the beta structure is preserved. The sequence of the native Aβ42 along with the mutated variants with the specific amino acid mutation is shown in Scheme 1. The sites in the Aβ42 residues which are mutated in the cases under study are shown in Figure 7 . Based on the abovementioned observation the coordinates of the wild type structure are appropriately mutated with amino acid residues specific for each mutant to generate the initial structure.
The Aβ42 has multiple binding sites for the tracers where they may be classified as surface binding sites and core binding sites. In our previous studies it was shown that the core binding sites are predominately dictating the tracer binding affinity trends so in this study we are restricting ourselves with the core binding sites. Three possible core sites are identified where two sites are present in the first conformer NMR structure and the site specific to phenylalanine is present in eight conformers of the NMR structure.
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Ligands
The PET tracers such as Florbetapir, Florbetaben, FPIB, AZD4694 and AZD2184 were used as the ligands in this study. Among these five ligands the first three ligands have been approved by FDA for clinical purpose. The last two have been studied earlier with these mutant systems. The chemical structure of the ligands under study is shown in Figure 8 .
Docking
The wild type Aβ42 structure is used as present in the NMR structure whereas in the case of the mutated Aβ42 the system is relaxed. In case of the mutated systems Aβ42 is equilibrated in Amber 14 using FF99SBildn parameters with 12 Å solvation using TIP3P parameters (counterions were added to make the system neutral) at 300 K and 1atm pressure for 1ns. [30] [31] [32] The systems were minimized using the steepest descent algorithm followed by the equilibration process in which the side chain of the mutated residues are free to relax whereas other atoms are restrained with weak force (10 kcal/mol Å 2 ). The structure obtained from the equilibration process is used as the initial structure for docking in the case of mutant systems.
All the possible core sites are explored for the interaction with different ligand molecules using docking. Since the amyloid protofibril does not have well defined binding sites, blind docking has been carried out using the autodock software. 
Molecular dynamics simulations
Amber 14 package was used for the MD simulation. The low energy protein ligand docked complex is taken and are solvated with cubic box of TIP3P water molecules upto 12Å from their outermost coordinates. Counterions were added to make the system neutral. FF99SBildn parameters were used for the proteins and GAFF parameters were used for the ligand molecules (ESP charges using Gaussian (B3LYP/6-31G*) and Antechamber). [34] [35] [36] The systems were minimized using the steepest descent algorithm followed by the equilibration using NVT and NPT ensemble 100ps each, the temperature of the system was raised from 0 to 300K during NVT equilibration phase. The solute structure was constrained with a weak force (10kcal/mol Å 2 ) in the energy minimization and equilibration steps. Then the production run of 50ns in NPT ensemble was carried out for each system without any constraint. The temperature of the system was maintained at 300K and pressure was maintained at 1 atm, respectively. A 12 Å cutoff was set for short-range interactions, while the electrostatic interactions beyond the cutoff were computed with the particle mesh Ewald (PME) method. 37 Bonds involving hydrogen atoms were constrained with the SHAKE algorithm. A time step of 2 fs was used, and the trajectory was saved every 2 ps. The trajectories were visualized using the VMD and Pymol pograms.
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Structural Analysis
The structural analysis of the Aβ42 peptide from the simulated trajectory is carried out to monitor the structural changes induced in the Aβ42 due to the mutation. The root mean square deviation (RMSD) and number of backbone hydrogen bonds were calculated with respect to time. The secondary structural population of the peptide was calculated for the last 10 ns of the trajectory considering the first 40 ns as the equilibration time as the mutant systems have to evolve.
Binding Free Energy Calculations
The python script MMPBSA.py of Amber 14 was used to do Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculations, 40 which can be used to calculate the binding free energies of ligand with native Aβ42 and other mutant fibrils. The data from the last 10 ns of the MD trajectories were used for MM/GBSA calculations in the single trajectory mode; namely, the snapshots of ligand, protein, and complex were extracted from the same trajectory (once in 50 frames). This mode was efficient and has been used extensively in binding free energy calculations. 41 The average values and standard errors were calculated from the results of all the extracted snapshots. The residuewise contribution of MM/GBSA was also calculated for each system.
Supporting Information:
The individual comparative plots of RMSD and number of H-bonds of all the simulated systems are presented for clarity purpose.
S.No
Tracer S1 Table 2 . MM/GBSA calculated binding affinities (ΔGbind) of selected system at the S1 and S2 binding sites (energy in kcal/mol). 
